Treatment of Crohn's disease in pregnant women: Drug and multidisciplinary approaches

Treatment of Crohn's disease in pregnant women: Drug and multidisciplinary approaches

Author Cury, Didia Bismara Autor UNIFESP Google Scholar
Moss, Alan C. Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Ctr Inflammatory Bowel Dis
Harvard Med Sch
Beth Israel Deaconess Med Ctr
Abstract Inflammatory bowel disease affects a substantial number of women in their reproductive years. Pregnancy presents a number of challenges for clinicians and patients; the health of the baby needs to be balanced with the need to maintain remission in the mother. Historically, treatments for Crohn's disease (CD) were often discontinued during the pregnancy, or nursing period, due to concerns about teratogenicity. Fortunately, observational data has reported the relative safety of many agents used to treat CD, including 5-aminosalicylic acid, thiopurines, and tumor necrosis factor. Data on the long-term development outcomes of children exposed to these therapies in utero are still limited. It is most important that physicians educate the patient regarding the optimal time to conceive, discuss the possible risks, and together decide on the best management strategy. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
Keywords Pregnancy
Inflammatory bowel disease
Crohn's disease
Language English
Date 2014-07-21
Published in World Journal of Gastroenterology. Pleasanton: Baishideng Publishing Group Inc, v. 20, n. 27, p. 8790-8795, 2014.
ISSN 1007-9327 (Sherpa/Romeo, impact factor)
Publisher Baishideng Publishing Group Inc
Extent 8790-8795
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000339389600004

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account